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Background: Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway
regulates multiple cellular processes such as cell proliferation, evasion from apoptosis, migration, glucose
metabolism, protein synthesis and proper differentiation in immune cells. Kaposi sarcoma-associated herpesvirus
(KSHV), an oncogenic virus associated with several human malignancies, expresses a variety of latent and lytic
proteins able to activate PI3K/AKT pathway, promoting the growth of infected cells and a successful viral infection.
Results: We found that KSHV latent infection of THP-1 cells, a human monocytic cell line derived from an acute
monocytic leukemia patient, resulted in an increase of AKT phoshorylation, not susceptible to bortezomib-induced
dephosphorylation, compared to the mock-infected THP-1. Accordingly, THP-1-infected cells displayed increased
resistance to the bortezomib cytotoxic effect in comparison to the uninfected cells, which was counteracted by
pre-treatment with AKT-specific inhibitors. Finally, AKT hyperactivation by KSHV infection correlated with plasma
membrane exposure of glucose transporter GLUT1, particularly evident during bortezomib treatment. GLUT1
membrane trafficking is a characteristic of malignant cells and underlies a change of glucose metabolism that
ensures the survival to highly proliferating cells and render these cells highly dependent on glycolysis. GLUT1
membrane trafficking in KSHV-infected THP-1 cells indeed led to increased sensitivity to cell death induced by the
glycolysis inhibitor 2-Deoxy-D-glucose (2DG), further potentiated by its combination with bortezomib.
Conclusions: KSHV confers to the THP-1 infected cells an oncogenic potential by altering the phosphorylation,
expression and localization of key molecules that control cell survival and metabolism such as AKT and GLUT1. Such
modifications in one hand lead to resistance to cell death induced by some chemotherapeutic drugs such as
bortezomib, but on the other hand, offer an Achilles heel, rendering the infected cells more sensitive to other
treatments such as AKT or glycolysis inhibitors. These therapeutic strategies can be exploited in the anticancer
therapy of KSHV-associated malignancies.
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Kaposi sarcoma-associated herpesvirus (KSHV) is a
human gammaherpesvirus found in all forms of Kaposi’s
sarcoma (KS) and is also highly associated with two
lymphoproliferative disorders that are primary effusion
lymphoma (PEL) and multicentric Castleman’s disease
(MCD) [1]. KSHV is able to infect a variety of non
haematological and haematological cells such as B and T
lymphocytes, monocytes, macrophages and dendritic
cells (DC) that express the known KSHV receptors
[2-6], such as proteoglycan heparan sulphates (HS),
DC-SIGN and some integrins [7-10]. THP-1 is a mono-
cytic cell line derived from an acute monocytic leukemia
patient whose infection by KSHV has been previously
reported [11,12]. These cells support a latent viral infec-
tion that implies the expression of few viral proteins in
the majority of the infected cells that is sufficient to
subvert the expression of monocyte activation markers
and influence the cytokine release [12]. Among the molecu-
lar pathways altered in tumor cells harboring KSHV, or
following KSHV de-novo infection is phosphatidylinositol-
3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) [13,14], which is an ubiquitous pathway that
controls cell survival and cell metabolism [15,16]. PI3Ks
are divided into four classes that have different substrate
specificities. Among them class I catalyzes the phosphoryl-
ation of phosphatidylinositol-4,5-bisphosphate (PIP2) into
phosphatidylinositol-3,4,5-triphosphate (PIP3) which has
a pivotal role in the control of cell growth, survival and
motility. PIP3 dephosphorylation is catalyzed by phos-
phatase and tensin homolog (PTEN), which is a phos-
phatase frequently mutated or deleted in cancers [17].
The hyperactivation of AKT, due to activation of class I
PI3K or to PTEN mutations/deletion, promotes cellular
proliferation, glucose metabolism, protein synthesis and
increases evasion from apoptosis induction by inactivating
pro-apoptotic proteins [18,19]. AKT pathway can be acti-
vated in KSHV-infected cells as a consequence of the ex-
pression of viral proteins that interfere with PTEN [20,21],
or directly activate PI3K [14]. AKT stimulates glycolysis by
increasing the expression and membrane translocation of
glucose transporters (i.e., GLUT1) which correlates with
decreased response to therapy, as also reported by our
studies [22], and overall survival in many cancer patients
[16]. GLUT1 up-regulation and membrane exposure is in-
deed intricately linked to cancer progression since cancer
cells need to support high proliferation rates and thus re-
quire efficient biosynthesis of macromolecules [23]. Con-
sequently, signals leading to increased proliferation must
also drive the necessary adaptation to the new metabolic
needs [24].
Here we evaluated the impact of KSHV-mediated AKT
hyperphosphorylation in THP-1 infected cells and how it
could be possible to inhibit this pathway. We show thatKSHV-latent infection of THP-1 cells resulted in AKT
hyperactivation that correlated with an higher resistance
to the treatment with proteasome inhibitor bortezomib,
whose cytotoxic effect can be mediated also by reducing
AKT phosphorylation in several tumor cell types [25-27].
AKT hyperphosphorylation by KSHV correlated with
GLUT1 plasma-membrane exposure on the cell surface in
THP-1 cells. Treatment of THP-1 infected cells or Pri-
mary Effusion Lymphoma (PEL) cells, harboring KSHV,
with 2-Deoxy-D-glucose (2DG), a glycolysis inhibitor re-
ported to induce a cytotoxic effect in cancer cells [28],
allowed efficient cell death that was further increased by
combination with bortezomib. Our study reinforces the
growing interest of metabolic perturbation in cancer ther-
apy and highlights the potential use of the combination of
bortezomib and 2DG as an anticancer treatment of
KSHV-associated malignancies.Materials and methods
Cell cultures and reagents
Human monocytic cell line THP-1 and primary effusion
lymphoma (PEL) were cultured in RPMI 1640 (Sigma,
St. Louis, MO, USA; cat no. R0883) supplemented with
10% fetal bovine serum (Euroclone, Milan, Italy; cat no.
ECLS0180L), glutamine (300 g/ml), streptomycin (100 g/ml)
and penicillin (100U/ml, Gibco Carlsbad, CA, USA; cat
no. 10378-016) in 5% CO2 at 37°C.
2-Deoxy-D-glucose (2DG) (Sigma cat no. D8375) was
used at 10mM, Bortezomib (Santa Cruz, CA, USA; cat
no. sc-217785) and AKT inhibitor LY294002 (Sigma cat
no. P0037) were used at concentration of 10 nM and 1 μM
respectively.Virus and infection
KSHV virus produced from BCBL-1 cell line was used to
infect THP-1 cells, as previously reported [29]. Briefly,
THP-1 cells were pelleted and incubated with KSHV
(200X) at 37°C for 1h. Cells were then plated in
complete medium and used for further treatments.Cell viability analysis
Cells were seeded in 24-well plates in complete medium
and treated with Ly294002 (10μM), bortezomib (10nM),
2DG (10 mM) or 2DG (10 mM)/bortezomib (10nM).
When LY294002 and bortezomib were used in combin-
ation, cells were pretreated with LY294002 for 40 min
before adding bortezomib. After 24h or 48h of treat-
ment (for BCBL-1 and THP1 respectively) cells were
collected, counted by trypan-blue exclusion assay using
a hemocytometer; cell pellets were used for western blot
analysis. Each experiment was performed in triplicate.
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Western Blot analysis was performed as described else-
where [30]. Briefly, cell were lysed in modified RIPA buffer
(150 mM NaCl, 1% NP40, 50 mM Tris–HCl pH8, 0,5%
deoxycholic acid, 0,1% SDS, 1% Triton X-100 protease
and phosphatase inhibitor), equal amount of lysates were
loaded on 4-12% NuPage Bis tris gels (Life technologies
cat no. NO0322BOX) electrophoresed and transferred to
Nitrocellulose membrane (Whatman, GE Healthcare, cat.
no. 10401196). Membranes were then blocked for 30 min
at RT in PBS containing BSA 3% and 0,2% Tween-20 and
then probed with primary antibody overnight at 4°C. After
3 washes in PBS-0,2% Tween 20, membranes were incu-
bated for 45 min with the appropriate horseradish
peroxidase-conjugated secondary antibody (Santa Cruz
biotechnologies) then washed as described before and
the blots were developed using ECL Blotting Substrate
(Thermo Scientific, Rockford, IL, USA; cat no. 32209).
The following antibodies were used: mouse monoclonal
anti β-actin (Sigma cat. no. A2228), rabbit polyclonal anti
Phospho-Akt (Ser473) (Cell Signaling cat.9271), rabbit
polyclonal anti Akt (Cell Signaling cat.9272), rabbit poly-
clonal anti cleaved PARP (p-85, cell signaling cat. 9542),
rabbit polyclonal anti GLUT1 (Santa Cruz cat no. sc-7903).
Immunofluorescence
Cells were seeded on multispot slides, fixed for 10 min in
cold methanol (−20°C) and incubated with the following
primary antibodies for 1h at room temperature (RT):
mouse anti LANA (Novus Biologicals cat no. NBP1-30176)
and rabbit anti GLUT-1 (Santa Cruz cat no. sc-7903).
After incubation with appropriate conjugate secondary
antibody (30 min at RT), cell were stained with DAPI.
Finally, microscope slides were mounted using PBS-
Glicerol 1:1 and visualized by a Apotome Axio Observer
Z1 inverted microscope (Zeiss, Oberkochen, Germany),
equipped with an AxioCam MRM Rev.3 camera at 40 ×
magnification.
Cell fractionation and membrane preparation
Cell fractionation was performed as described else-
where [31]. Briefly, treated and untreated THP-1 cells
were harvested, washed with PBS and resuspended in
HEM buffer (20 mM HEPES (N-2-hydroxyethylpipera-
zine-N’-2-ethanesulfonic acid), 1 mM EDTA, 1 mM 2-
mercaptoethanol and protease inhibitors). Cells were
Dounce homogenized and nuclei were collected by
centrifugation at 750 × g for 5 min. Cell extracts were
kept at 4°C for 5 min and the remaining intact nuclei
were collected by a further centrifugation at 750 × g for
5 min. The supernatant was recovered and a crude
membrane fraction was obtained by centrifugation at
43,000 × g for 20 min. The leftover supernatant repre-
sented the cytoplasmic fraction. Nuclear and membranefractions were than separated on SDS-PAGE, transferred
to nitrocellulose membrane (GE Healthcare) and analyzed
by western blot with the appropriate antibodies.Statistics
All experiment unless indicated were performed at least
three times. All experimental results were expressed as
the arithmetic mean ± standard deviation (s.d.). Student’s
t-test was used for statistical significance of the differ-
ences between treatment groups. Statistical analysis was
performed using analysis of variance at 5% (p < 0.05) or
1% (p < 0.01).Results and discussion
KSHV-latent infection of monocytic cell line THP-1 results
in an increase of AKT phosphorylation that persisted after
bortezomib treatment
THP-1 monocytic cells, infected with KHSV for 48 hours,
were subjected to immunofluorescence analysis and, as
shown in Figure 1A, the expression of latent associated
nuclear antigen (LANA) was detected in about 35% of the
cells, compared to mock infected cells. No expression of
lytic antigens was found (data not shown), in accordance
to previous reported studies [12], indicating that KSHV
establishes a latent infection in THP-1 cells. Next, we in-
vestigated the impact of KHSV-infection on AKT phos-
phorylation in THP-1 cells. Western blot analysis showed
that THP-1-infected cells displayed increased phosphoryl-
ation of AKT, in comparison to THP-1 mock-infected
cells (Figure 1B). This is in agreement with other studies
showing that KSHV proteins are able to activate PI3K/
AKT pathway or down-regulate AKT phosphatases such
as PTEN in several cell types [14,20]. The activation of
AKT pathway has been also reported for other oncov-
iruses [32]. As bortezomib has been shown to interfere
with the activation status of AKT [27,33], we then in-
vestigated if bortezomib-treatment could affect AKT
phosphorylation in THP-1 cells. We observed that
bortezomib (Bz, 10 nM for 48 hours) strongly down-
regulated AKT phosphorylation in mock-infected cells,
while KSHV infection impaired such effect (Figure 1B).
This might be due to KSHV-induced inhibition of PTEN,
demonstrated in other studies [20], that could counteract
the bortezomib-mediated up-regulation of this phosphat-
ase [34]. As expected, AKT phosporylation was completely
abolished by pre-treatment with AKT inhibitor LY294002,
both in mock and viral-infected cells (Figure 1B). By inhi-
biting AKT phosphorylation we also observed a reduction
of the total AKT protein, likely due to its reduced stability
in the unphosphorylated state. Similar results were ob-
tained inhibiting AKT phosphorylation with mTOR kinase
inhibitor PP242 (data not shown).
Figure 1 Hyperphosphorylation of Akt induced by KSHV in THP-1 infected cells is resistant to Bortezomib treatment. A)
Immunofluorescence of mock and KSHV-infected THP-1 cells with anti-LANA antibodies. Typical LANA staining (intranuclear red punctuation) is
visible in cells latently infected by KSHV. The counterstaining of THP-1 DNA with DAPI (blue) is shown. B) Western blot analysis of phospho-Akt
(p-AKT) and total AKT (AKT) in mock and KSHV-infected THP-1 cells, untreated or treated with Bortezomib (Bz, 10 nM), or LY294002 (Ly, 1μM) or
combination of both (Bz, 10 nM plus Ly, 1μM). β-actin is included as protein loading control.
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with a reduction of bortezomib cytotoxic effect
One of the main molecular events of the bortezomib-
induced cytotoxic effect is the down-regulation of AKT-
phosphorylation, that can also be considered a biomarker
for predicting chemoterapeutic response in some tumors
[27,33]. Hence, we next investigated the biological effect
of bortezomib-treatment with or without AKT inhibitor
LY294002. The results, obtained by a trypan-blue exclu-
sion viability assay, indicated that 10 nM bortezomib
efficiently induced THP-1 mock-infected cell death that
was not further increased by combination with AKT in-
hibitor LY294002 (Figure 2A). In contrast, the negligible
cell death induced by bortezomib in THP-1 KSHV-
infected cells was significantly increased by AKT inhibi-
tor LY294002 (Figure 2A). These data are in accordance
with modification of AKT phosphorylation seen in
Figure 1B. Moreover, apoptotic marker PARP cleavage
was induced in bortezomib-treated mock-infected THP-
1 cells and slightly increased by combination with AKT
inhibitor LY294002 (Figure 2B). On the contrary, the
impairment of PARP cleavage upon bortezomib treat-
ment in KSHV-infected cells was efficiently reverted by
combination with LY294002 (Figure 2B), confirming the
role of AKT activation in the resistance to bortezomib
treatment of THP-1 KSHV-infected cells. These results
suggest the possibility to increase the bortezomib-
cytotoxic effect by counteracting the KSHV-mediated
AKT hyperactivation in THP-1 monocytic cells. The
importance of the activation of AKT pathway in thecontrol of cell survival has been previously reported in
other lymphoma cell lines [35].
AKT hyperactivation by KSHV is responsible for GLUT 1
membrane exposure, particularly during bortezomib-
treatment
The activation of PI3K/AKT pathway in cancer cells has
been shown to influence the plasma membrane trafficking
of one of the most ubiquitous glucose transporter
molecule such as GLUT1 [36,37]. The exposure of
GLUT1 on the cell surface up-regulates the glucose influx
into the cells and gives a proliferating advantage to cells
such as cancer cells that use this molecule as principal
energetic source. This effect, described long time ago as
Warburg effect [38], indicates the dependance of cancer
cells on glycolysis also in aerobic conditions and helps
these cells to survive in the hypoxic conditions typical of
tumor microenviroment. KSHV has been previously
reported to induce Warburg effect in endothelial cells
through AKT activation and also a metabolic reprogram-
ming in PEL cells [39,40]. An alteration of glucose metab-
olism has been described also for other oncogenic viruses
[41,42]. Immunofluorescence analysis shows that KSHV
infection (KSHV+) induced GLUT1 exposure on THP-1
cell membranes, compared to mock-infected cells (KSHV -),
that was further increased following bortezomib treatment
(Figure 3A). In agreement with the virus-induced AKT
phosphorylation, GLUT1 membrane exposure was blocked
by bortezomib combination with AKT inhibitor LY294002
in KSHV-infected THP-1 cells (Figure 3A).
Figure 3 GLUT1 membrane exposure, induced by KSHV infection of THP-1 cells, increases after Bortezomib treatment. A) GLUT1
Immunofluorescence in mock and KSHV-infected THP-1 cells in the presence of Bortezomib (Bz), LY294002 (Ly) or the combination of them (Ly + Bz).
GLUT1 staining (red) is mainly accumulated at the membranes on ~ 15% of KSHV-infected cells mock treated and in ~ 40% of the KSHV-infected
cells upon bortezomib treatment. The counterstaining of THP-1 DNA with DAPI (blue) is shown. B) Western blot analysis showing the
expression of GLUT1 in membrane fraction of mock and KSHV-infected THP-1 cells untreated or treated with bortezomib (Bz), LY294002 (Ly) or
both (Ly + Bz). Ponceau staining of the membrane is reported as loading control.
Figure 2 KSHV-mediated AKT hyperphosphorylation correlates with a reduction of Bortezomib cytotoxic effect. A) THP-1 mock and
KSHV-infected cells were treated with bortezomib (Bz,10nM, for 48h) or AKT inhibitor LY294002 (Ly, 1μM) or combination of both (Bz, 10 nM plus
Ly, 1μM). Cell death measurements were assayed by trypan-blue staining. The result is the mean ± SD of three independent experiments
performed in duplicates. *p = 0.01. B) Western blot analysis of Cleaved-PARP of mock and THP-1-KSHV-infected cells untreated or treated with
bortezomib (BZ), LY294002 (Ly) or both (Ly + BZ). β-actin is included as protein loading control.
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Figure 4 KSHV latent infection induces 2-Deoxy-D-glucose cytotoxicity, further increased by its combination with bortezomib. A) THP-1
mock and KSHV-infected cells were treated with bortezomib (BZ, 10 nM, for 48h) with or without glycolysis inhibitor 2DG (10 mM). Cell death
measurements were assayed by trypan-blue staining. The result is the mean ± SD of three independent experiments performed in duplicates. *p = 0.01;
**p = 0.001. B) Western blot analysis showing the expression of cleaved PARP in THP-1 mock and KSHV-infected cells treated with 2DG, Bz and 2DG +
Bz. β-actin is included as protein loading control. C) BCBL1 and BC3 PEL cells were treated with bortezomib (Bz, 10 nM, for 48h) with or without
glycolysis inhibitor 2DG (10 mM). Cell death measurements were assayed by tripan blue staining. The result is the mean ± SD of three
indipendent experiments performed in duplicates. *p = 0.01, **p = 0.001; ∇p < 0.05, ∇∇p =0.05. D) Western blot analysis showing the expression
of cleaved PARP in BCBL-1 and BC3 cells following treatment with 2DG, 2DG + Bz and Bz. β-actin is included as protein loading control.
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induced by KSHV in THP-1 was confirmed by western
blot analysis of membrane extracts of infected and unin-
fected cells (Figure 3B). According to the immunofluor-
escence results, bortezomib treatment further increased
the membrane expression of GLUT1 in THP-1-KSHV-
infected cells, likely due to the inhibition of its proteasomal
degradation mediated by bortezomib. GLUT1 exposure
was completely abolished by pre-treatment with AKT in-
hibitor LY294002 (Figure 3B). As equal loading control,
the ponceau membrane staining was included.
KSHV-infection induces 2-Deoxy-D-glucose cytoxicity,
further increased by its combination with bortezomib
Cancer cells displaying elevated membrane expression
of GLUT1 are highly dependent on glycolysis for their
survival, therefore, glycolysis inhibition is an interesting
anticancer strategy [23]. To test this outcome, we
exposed THP-1 KSHV-infected cells to the glycolysis
inhibitor 2-Deoxy-D-glucose (2DG) with or without
bortezomib treatment. We found that blocking glycoly-
sis with 2DG treatment induced cell death in THP-1
infected cells and to a lesser extent also in the mock
infected cells (Figure 4A). Interestingly though, 2DG
treatment significantly increased bortezomib-induced
cell death in KSHV-infected THP-1 cells, while it did
not further increase the bortezomib-induced cell death
in mock-infected cells (Figure 4A). Similar results were
also obtained in BCBL-1 and BC3 primary effusion
lymphoma (PEL) cell lines, that are latently infected by
KSHV (Figure 4C). We previously reported that borte-
zomib induced immunogenic cell death in BCBL-1 cells
[43,44] and here we found that such a cell death was
significantly increased following 2DG co-treatment that
was also cytotoxic by itself (Figure 4C). The cell death
results, in THP-1, BCBL-1 and BC3 cells were con-
firmed by western immunoblotting of PARP cleavage, as
shown in Figure 4B and D. These findings strengthen
the use of glycolysis inhibition in combination with Bz
in the KSHV de novo infected cells and in KSHV-
associated tumor cells.
Conclusions
The knowledge of the pathways and their downstream
effectors that confer a growth advantage to cancer cells
is of pivotal importance in the attempt to revert their
pro-survival effects into an Achilles’ heel. Our results in-
dicate that KSHV increases the oncogenic potential of
the THP1-infected cells by hyper-activating PI3K/AKT
pathway. This leads to an increase of bortezomib-
resistance and to a GLUT1 plasma-membrane exposure.
However we found that these pro-survival effects turned
out to be detrimental for cell survival when AKT or gly-
colysis inhibitors were used, particularly in combinationwith bortezomib. These data encourage the use of such a
combination treatment as a therapeutic strategy against
KSHV associated malignancies.
Abbreviations
2DG: 2-Deoxy-D-glucose; GLUT1: Glucose transporter 1; KSHV: Kaposi
sarcoma-associated herpesvirus; LANA: Latency-associated nuclear antigen;
MCD: Multicentric Castleman’s disease; PEL: Primary effusion lymphoma;
PI3K: Phosphatidylinositol-3-kinase; PIP2: Phosphatidylinositol-4,5-bisphosphate;
PIP3: Phosphatidylinositol-3,4,5-triphosphate; PTEN: Phosphatase and tensin
homolog; Bz: Bortezomib.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived the experiments: MC, RG, RS. Performed Western blot analysis: RG,
AF and MG. Performed Immunofluorescence analysis: RS, RG. Interpretation
of results and wrote the paper: MC, AF, GDO. All authors read and approved
the final manuscript.
Acknowledgements
We thank Sandro Valia for photographic work.
We thank Marina Peddis, Giulia Di Giovenale and Valentina Lacconi for
technical help.
Funding
This work was supported by grants from MIUR, Associazione Italiana per la
ricerca sul Cancro (AIRC) (Grant n. 10265), and Pasteur Cenci-Bolognetti
foundation.
Author details
1Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci
Bolognetti, La Sapienza University, 00161 Rome, Italy. 2Department of
Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio”,
66013 Chieti, Italy. 3Department of Experimental Oncology, Regina Elena
National Cancer Institute, 00158 Rome, Italy.
Received: 19 September 2013 Accepted: 10 October 2013
Published: 23 October 2013
References
1. Boshoff C, Weiss R: AIDS-related malignancies. Nat Rev Cancer 2002,
2:373–382.
2. Chakraborty S, Veettil MV, Chandran B: Kaposi’s Sarcoma associated
herpesvirus entry into target cells. Front Microbiol 2012, 3:6.
3. Jeffery HC, Wheat RL, Blackbourn DJ, Nash GB, Butler LM: Infection and
transmission dynamics of rKSHV.219 In primary endothelial cells. J Virol
Methods 2013, 193:251–259.
4. Chandran B: Early events in Kaposi’s sarcoma-associated herpesvirus
infection of target cells. J Virol 2010, 84:2188–2199.
5. Hassman LM, Ellison TJ, Kedes DH: KSHV infects a subset of human
tonsillar B cells, driving proliferation and plasmablast differentiation.
J Clin Invest 2011, 121:752–768.
6. Cirone M, Lucania G, Bergamo P, Trivedi P, Frati L, Faggioni A: Human
herpesvirus 8 (HHV-8) inhibits monocyte differentiation into dendritic
cells and impairs their immunostimulatory activity. Immunol Lett 2007,
113:40–46.
7. Birkmann A, Mahr K, Ensser A, Yaguboglu S, Titgemeyer F, Fleckenstein B,
Neipel F: Cell surface heparan sulfate is a receptor for human
herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol 2001,
75:11583–11593.
8. Kerur N, Veettil MV, Sharma-Walia N, Sadagopan S, Bottero V, Paul AG,
Chandran B: Characterization of entry and infection of monocytic THP-1
cells by Kaposi’s sarcoma associated herpesvirus (KSHV): role of heparan
sulfate, DC-SIGN, integrins and signaling. Virol 2010, 406:103–116.
9. Rappocciolo G, Jenkins FJ, Hensler HR, Piazza P, Jais M, Borowski L, Watkins
SC, Rinaldo CR Jr: DC-SIGN is a receptor for human herpesvirus 8 on
dendritic cells and macrophages. J Immunol 2006, 176:1741–1749.
Gonnella et al. Journal of Experimental & Clinical Cancer Research 2013, 32:79 Page 8 of 8
http://www.jeccr.com/content/32/1/7910. Rappocciolo G, Hensler HR, Jais M, Reinhart TA, Pegu A, Jenkins FJ, Rinaldo
CR: Human herpesvirus 8 infects and replicates in primary cultures of
activated B lymphocytes through DC-SIGN. J Virol 2008, 82:4793–4806.
11. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K:
Establishment and characterization of a human acute monocytic
leukemia cell line (THP-1). Int J Cancer 1980, 26:171–176.
12. Gregory SM, Wang L, West JA, Dittmer DP, Damania B: Latent Kaposi’s
sarcoma-associated herpesvirus infection of monocytes downregulates
expression of adaptive immune response costimulatory receptors and
proinflammatory cytokines. J Virol 2012, 86:3916–3923.
13. Wang L, Damania B: Kaposi’s sarcoma-associated herpesvirus confers a
survival advantage to endothelial cells. Cancer Res 2008, 68:4640–4648.
14. Bhatt AP, Damania B: AKTivation of PI3K/AKT/mTOR signaling pathway by
KSHV. Front Immunol 2012, 3:401.
15. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-
Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004,
30:193–204.
16. Ward PS, Thompson CB: Signaling in control of cell growth and
metabolism. Cold Spring Harb Perspect Biol 2012, 4:a006783.
17. Shi Y, Paluch BE, Wang X, Jiang X: PTEN at a glance. J Cell Sci 2012,
125:4687–4692.
18. Pal I, Mandal M: PI3K And Akt as molecular targets for cancer therapy:
current clinical outcomes. Acta Pharmacol Sin 2012, 33:1441–1458.
19. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three akts.
Genes Dev 1999, 13:2905–2927.
20. Tomlinson CC, Damania B: The K1 protein of Kaposi’s sarcoma-associated
herpesvirus activates the Akt signaling pathway. J Virol 2004,
78:1918–1927.
21. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, Sawai ET,
Gutkind JS: Akt plays a central role in sarcomagenesis induced by
Kaposi’s sarcoma herpesvirus-encoded G protein-coupled receptor.
Proc Natl Acad Sci USA 2004, 101:4821–4826.
22. Garufi A, Ricci A, Trisciuoglio D, Iorio E, Carpinelli G, Pistritto G, Cirone M,
D’Orazi G: Glucose restriction induces cell death in parental but not in
homeodomain-interacting protein kinase 2-depleted RKO colon cancer
cells: molecular mechanisms and implications for tumor therapy.
Cell Death Dis 2013, 4:e639.
23. Munoz-Pinedo C, El Mjiyad N, Ricci JE: Cancer metabolism: current
perspectives and future directions. Cell Death Dis 2012, 3:e248.
24. Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark
even Warburg did not anticipate. Cancer Cell 2012, 21:297–308.
25. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF: CIP2A is a target
of bortezomib in human triple negative breast cancer cells. Breast Cancer
Res 2012, 14:R68.
26. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF:
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-
induced apoptosis in leukemia cells. Haematol 2013, 98:729–738.
27. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL: Down-regulation of
phospho-Akt is a major molecular determinant of bortezomib-induced
apoptosis in hepatocellular carcinoma cells. Cancer Res 2008,
68:6698–6707.
28. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P,
Schwartz L, Icard P: Effect of 2-deoxy-D-glucose on various malignant cell
lines in vitro. Anticancer Res 2006, 26:3561–3566.
29. Santarelli R, Farina A, Granato M, Gonnella R, Raffa S, Leone L, Bei R, Modesti
A, Frati L, Torrisi MR, Faggioni A: Identification and characterization of the
product encoded by ORF69 of Kaposi’s sarcoma-associated herpesvirus.
J Virol 2008, 82:4562–4572.
30. Cuozzo F, Raciti M, Bertelli L, Parente R, Di Renzo L: Pro-death and pro-
survival properties of ouabain in U937 lymphoma derived cells. J Exp Clin
Cancer Res 2012, 31:95.
31. Fries KL, Sculley TB, Webster-Cyriaque J, Rajadurai P, Sadler RH, Raab-Traub
N: Identification of a novel protein encoded by the BamHI a region of
the Epstein-Barr virus. J Virol 1997, 71:2765–2771.
32. Paolini F, Carbone A, Benevolo M, Silipo V, Rollo F, Covello R, Piemonte P,
Frascione P, Capizzi R, Catricala C, Venuti A: Human papillomaviruses,
p16INK4a and Akt expression in basal cell carcinoma. J Exp Clin Cancer
Res 2011, 30:108.
33. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL: CIP2A
Mediates effects of bortezomib on phospho-Akt and apoptosis in
hepatocellular carcinoma cells. Oncogene 2010, 29:6257–6266.34. Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H,
Tsukuda K, Ogasawara Y, Shimizu N: Proteasome inhibitor bortezomib
increases PTEN expression and enhances trastuzumab-induced growth
inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006,
17:455–462.
35. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y: Down-regulation of
the PI3K/Akt signaling pathway and induction of apoptosis in CA46
burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 2012, 31:48.
36. Wieman HL, Wofford JA, Rathmell JC: Cytokine stimulation promotes
glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1
activity and trafficking. Mol Biol Cell 2007, 18:1437–1446.
37. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J: Wide
expression of the human erythrocyte glucose transporter Glut1 in
human cancers. Cancer Res 1996, 56:1164–1167.
38. Warburg O: On the origin of cancer cells. Sci 1956, 123:309–314.
39. Delgado T, Carroll PA, Punjabi AS, Margineantu D, Hockenbery DM,
Lagunoff M: Induction of the Warburg effect by Kaposi’s sarcoma
herpesvirus is required for the maintenance of latently infected
endothelial cells. Proc Natl Acad Sci USA 2010, 107:10696–10701.
40. Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC, Dittmer DP,
Damania B: Dysregulation of fatty acid synthesis and glycolysis in non-
Hodgkin lymphoma. Proc Natl Acad Sci USA 2012, 109:11818–11823.
41. Noch E, Khalili K: Oncogenic viruses and tumor glucose metabolism: like
kids in a candy store. Mol Cancer Ther 2012, 11:14–23.
42. Darekar S, Georgiou K, Yurchenko M, Yenamandra SP, Chachami G, Simos G,
Klein G, Kashuba E: Epstein-Barr virus immortalization of human B-cells
leads to stabilization of hypoxia-induced factor 1 alpha, congruent with
the Warburg effect. PloS one 2012, 7:e42072.
43. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R,
Frati L, Faggioni A: Primary effusion lymphoma cell death induced by
bortezomib and AG 490 activates dendritic cells through CD91. PloS one
2012, 7:e31732.
44. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R,
Frati L, Faggioni A: Activation of dendritic cells by tumor cell death.
Oncoimmunology 2012, 1:1218–1219.
doi:10.1186/1756-9966-32-79
Cite this article as: Gonnella et al.: Kaposi sarcoma associated
herpesvirus (KSHV) induces AKT hyperphosphorylation,
bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-
1 monocytic cell line. Journal of Experimental & Clinical Cancer Research
2013 32:79.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
